Nano cap Can-Fite BioPharma (NYSEMKT:CANF) is the latest company to take advantage of the market’s enthusiasm for anything coronavirus-related.
This morning, it announced that
it is now exploring a collaboration to evaluate Piclidenoson (CF101)
for the potential treatment of coronavirus infection, considering
reports that rheumatoid arthritis (RA) drugs may show efficacy for this
use.
Interim data from a Phase 3 study in RA should be available in Q4.
https://seekingalpha.com/news/3548976-can-fite-joins-coronavirus-wave-up-36-premarket
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.